Advancing Novel Therapeutics to Elevate the Standard of Care

Development Programs

AngioGenex is committed to the discovery and advancement of new medicines that have the potential to relieve suffering and improve quality of life for patients in need.

AGX-A is a Novel Id Protein Inhibitor

AGX-A is a small molecule therapeutic that has been rationally designed and targeted against certain cancers and age-related macular degeneration. AGX-A works by inhibiting the activity of Id proteins.

Cholangiocarcinoma is a Cancer that Forms in Bile Ducts

Cholangiocarcinoma is cancer of the bile ducts. Bile ducts the digestive fluid bile and connect your liver to your gallbladder and small intestine. Also known as bile duct cancer, cholangiocarcinoma is very difficult to treat. Fewer than 20,000 cases occur each year in the U.S. and the 5 year survival rate with surgery and standard chemotherapy can be as low as 10%.

AMD is the Leading Cause of Vision Loss in People 60+

Wet age-related macular degeneration (AMD) is characterized by pathologic angiogenesis in the posterior segment of the eye, which interfere with retinal function and is the leading causes of vision loss in adults 60+. When the cells of the macula deteriorate, images are not received correctly. AGX51, a legacy compound, was well-tolerated in mice and demonstrated the potential to mediate the degradation of Id protein, which could potentially lead to a reduction in retinal neovascularization, a key contributor to vision loss in AMD.